Antibody Discovery | Antibody sequencing & developability | Abzena


Phage display, sequencing and developability assessment

The biopharmaceutical development process starts with target identification and antibody discovery. Abzena offers multiple approaches to antibody discovery and the isolation, development and selection of lead antibodies.

shutterstock_389524267-1-e147437106926521Antibody Discovery

Abzena’s antibody discovery capability is based on the latest and most efficient hybridoma generation technologies coupled with high throughput robotic colony picking and liquid handling for highly efficient hybridoma screening. Read more >>>

shutterstock_389524267-1-e1474371069265212Hybridoma Sequencing

Abzena’s platform for mRNA sequencing can determine the DNA and amino acid sequence of your antibody. Sequencing can be performed for IgG and IgM monoclonal antibodies produced by human, mouse and rat hybridoma cell lines. Read more >>>

shutterstock_389524267-1-e1474371069265213Developability Assessment

Many physicochemical modifications can adversely impact on the molecular integrity of biologic molecules. Abzena can perform an in silico assessment to identify a number of potential sequence liabilities which, if not addressed, could lead to manufacturing challenges at a later stage. Read more >>>

Interested in our services? Get In Touch